What Makes SAFER Better? It Goes Beyond.
The clinician-rated Massachusetts General Hospital SAFER interview facilitates assessment of important supplemental factors that go beyond conventional diagnostic criteria and symptom severity to identify patients who would be valid for clinical trials.
- SAFER increases the quality of your clinical trials by improving the separation of placebo responders from active drug responders and by restricting the sample to a tightly defined population.
- SAFER ensures the risk is minimized that factors unrelated to treatment may determine the patient’s outcome.
- When needed, our raters will present patient profiles to peers, who weigh in quickly to make a solid and speedy decision on the appropriateness of the patient.
The SAFER interview confirms that the illness is a specific state, and excludes patients with any symptoms that are nonspecific or not readily assessable.